All Sections to PDF Report

Clearfield, Inc., 12-31-17 - 10-Q - 2018

12-31-17 - v3, Generated by: GlobeNewswire Admin, 01/29/18, 11:06 AM EST

This XBRL rendering is intended for proofing purposes only.

Cover
Financial Statements
Notes To Financial Statements
Notes Tables
Notes Details

XBRL rendered proof was created using the SEC XBRL Rendering Engine Code Release #2.4.1.9. The source is available from the SEC website.

D	3 Months Ended	
Document And Entity Information	Dec. 31, 2017	Jan. 25, 2018
Document Information [Line Items]		
Entity Registrant Name	Clearfield, Inc.	
Entity Central Index Key	0000796505	
Trading Symbol	clfd	
Current Fiscal Year End Date	09-30	
Entity Filer Category	Accelerated Filer	
Entity Current Reporting Status	Yes	
Entity Voluntary Filers	No	
Entity Well-known Seasoned Issuer	No	
Entity Common Stock, Shares Outstanding (in shares)		13,817,859
Document Type	10-Q	
Document Period End Date	Dec. 31, 2017	
Document Fiscal Year Focus	2018	
Document Fiscal Period Focus	Q1	
Amendment Flag	false	

Condensed Balance Sheets (Current Period Unaudited) (USD \$)	Dec. 31, 2017	Sep. 30, 2017
Current Assets		
Cash and cash equivalents	\$ 20,453,030	\$ 18,536,111
Short-term investments	5,385,150	5,937,150
Accounts receivables, net	5,570,721	7,237,641
Inventories	8,140,384	8,453,567
Other current assets	939,326	978,933
Total current assets	40,488,611	41,143,402
Property, plant and equipment, net	5,201,901	5,434,172
Other Assets		
Long-term investments	20,357,000	19,816,000
Goodwill	2,570,511	2,570,511
Other	552,331	529,952
Total other assets	23,479,842	22,916,463
Total Assets	69,170,354	69,494,037
Current Liabilities		
Accounts payable	1,205,223	1,739,791
Accrued compensation	1,443,883	2,410,026
Accrued expenses	98,569	93,304
Total current liabilities	2,747,675	4,243,121
Other Liabilities		
Deferred taxes	60,076	444,076
Deferred rent	279,642	281,720
Total other liabilities	339,718	725,796
Total Liabilities	3,087,393	4,968,917
Commitments and Contingencies		
Shareholders' Equity		
Preferred stock, \$.01 par value; 500,000 shares; no shares issued or outstanding		
Common stock, authorized 50,000,000, \$.01 par value; 13,824,191 and 13,812,821, shares issued and outstanding at December 31, 2017 and September 30, 2017	138,242	138,128
Additional paid-in capital	56,021,457	55,406,888
Retained earnings	9,923,262	8,980,104
Total Shareholders' Equity	66,082,961	64,525,120
Total Liabilities and Shareholders' Equity	\$ 69,170,354	\$ 69,494,037

Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) (USD \$)	Dec. 31, 2017	Sep. 30, 2017
Preferred stock, par value (in dollars per share)	\$ 0.01	\$ 0.01
Preferred stock, authorized shares (in shares)	500,000	500,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	\$ 0.01	\$ 0.01
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	13,824,191	13,812,821
Common stock, shares outstanding (in shares)	13,824,191	13,812,821

Condensed Statements of Earnings	3 Months Ended		
(Unaudited) (USD \$)	Dec. 31, 2017	Dec. 31, 2016	
Net sales	\$ 16,866,884	\$ 18,266,162	
Cost of sales	9,758,477	11,057,442	

Gross profit	7,108,407	7,208,720	
Operating expenses			
Selling, general and administrative	6,463,971	6,017,524	
Income from operations	644,436	1,191,196	
Interest income	95,722	52,734	
Income before income taxes	740,158	1,243,930	
Income tax (benefit) expense	(203,000)	367,000	
Net income	\$ 943,158	\$ 876,930	
Net income per common share:			
Basic (in dollars per share)	\$ 0.07	\$ 0.06	
Diluted (in dollars per share)	\$ 0.07	\$ 0.06	
Weighted average shares outstanding:			
Basic (in shares)	13,443,945	13,567,484	
Diluted (in shares)	13,476,417	13,790,793	

Condensed Statements of Cash	3 Months Ended			
Flows (Unaudited) (USD \$)	Dec. 31, 2017	Dec. 31, 2016		
Net income	\$ 943,158	\$ 876,930		
Adjustments to reconcile net income to net cash provided by (used in) operating activities:				
Depreciation and amortization	436,198	388,625		
Deferred taxes	(384,000)			
Loss on disposal of assets	1,594			
Stock based compensation	483,287	593,746		
Changes in operating assets and liabilities:				
Accounts receivable	1,666,920	548,293		
Inventories	313,183	(341,490)		
Other assets	41,706	228,259		
Accounts payable, accrued expenses and deferred rent	(1,497,524)	(2,899,667)		
Net cash provided by (used in) operating activities	2,004,522	(605,304)		
Cash flows from investing activities				
Purchases of property, plant and equipment and intangible assets	(229,999)	(529,302)		
Purchases of investments	(2,466,000)	(7,440,000)		
Proceeds from maturities of investments	2,477,000	2,459,000		
Net cash used in investing activities	(218,999)	(5,510,302)		
Cash flows from financing activities				
Repurchases of common stock	(10,850)			
Proceeds from issuance of common stock under employee stock purchase plan	148,259	169,500		
Proceeds from issuance of common stock upon exercise of stock options	3,249	17		
Tax withholding related to vesting of restricted stock grants	(9,262)	(10,326)		
Net cash provided by financing activities	131,396	159,191		
Increase (decrease) in cash and cash equivalents	1,916,919	(5,956,415)		
Cash and cash equivalents, beginning of period	18,536,111	28,014,321		
Cash and cash equivalents, end of period	20,453,030	22,057,906		
Supplemental disclosures for cash flow information				
Cash paid during the year for income taxes	2,500	12,250		
Non-cash financing activities				
Cashless exercise of stock options	\$ 5,782	\$ 32,984		

Note 1 - Basis of Presentation	3 Months Ended
Note 1 - Basis of Fresentation	Dec. 31, 2017
Notes to Financial Statements	
Basis of Accounting [Text Block]	Note 1. Basis of Presentation

The accompanying (a) condensed balance sheet as of September 30, 2017, which has been derived from audited financial statements, and (b) unaudited interim condensed financial statements as of and for the three months ended December 31, 2017 have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial information, pursuant to the rules and regulations of the Securities and Exchange Commission. Pursuant to these rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. However, in the opinion of management, the financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the financial position and results of operations and cash flows of the interim periods presented. Operating results for the interim periods presented are not necessarily indicative of results to be expected for the full year or for any other interim period, due to variability in customer purchasing patterns and seasonal, operating and other factors. These condensed financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2017.

In preparation of the Company's financial statements, management is required to make estimates and assumptions that affect reported amounts of assets and liabilities and related revenues and expenses during the reporting periods. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates.

Note 2 - Net Income Per Share	3 Months Ended
Note 2 - Net Income Per Snare	Dec. 31, 2017
Notes to Financial Statements	
Earnings Per Share [Text Block]	Note 2. Net Income Per Share

Basic net income per common share ("EPS") is computed by dividing net income by the weighted average number of

common shares outstanding for the reporting period. Diluted EPS equals net income divided by the sum of the weighted average number of shares of common stock outstanding plus all additional common stock equivalents, such as stock options and restricted stock awards, when dilutive.

The following is a reconciliation of the numerator and denominator of the net income per common share computations for the three months ended December 31, 2017 and 2016:

Net income Weighted average common shares Dilutive potential common shares		Three Months Ended December 31,	
Weighted average common shares Dilutive potential common shares	2017		2016
Dilutive potential common shares	\$ 943,158	\$	876,930
•	13,443,945		13,567,484
Waishted assessed libeting assessed above section disc	32,472		223,309
Weighted average dilutive common shares outstanding	13,476,417		13,790,793
Net income per common share:			
Basic	\$ 0.07	\$	0.06
Diluted	\$ 0.07	\$	0.06

Note 3 - Cash, Cash Equivalents and	3 Months Ended			
Investments	Dec. 31, 2017			
Notes to Financial Statements				
Cash and Cash Equivalents Disclosure [Text Block]	Note 3. Cash, Cash Equivalents and Investments			
	The Company currently invests its excess cash in money market accounts term of not more than five years. CDs with original maturities of more than the investments and are carried at amortized cost. Investments maturing in less than on on the balance sheet, and investments maturing in one year or greater are classified. The maturity dates of the Company's CDs as of December 31, 2017 and September 30.	ree months are reporte e year are classified as as long term investmen	ed as he short ter	ld-to-maturity m investments
		December 31, 2017	Sep	tember 30, 2017
	Less than one year	\$ 5,385,150	\$	5,937,150
	1-5 years	20,357,000		19,816,000
	Total	\$ 25,742,150	\$	25,753,150

Note 4 - Stock Based Compensation	Dec. 31, 2017	
Notes to Financial Statements		
Costs, Share-based Payments [Text Block]	Note 4. Stock Based Compensation The Company recorded \$483,287 of compensation expense related to current and past restricted stock grants and the Company's Employee Stock Purchase Plan ("ESPP") for the three months ended December 31, 2017 of which \$441,257 is included in selling, general and administrative expense, and \$42,030 is included in cost of sales. The Company recorded \$593,746 of compensation expense related to current and past equity awards for the three months ended December 31, 2016 of which \$539,046 was included in selling, general and administrative expense, and \$54,700 was included in cost of sales. As of December 31, 2017, \$4,431,952 of total unrecognized compensation expense related to non-vested restricted stock awards is expected to be recognized over a period of approximately 6.8 years.	
	over a period of approximately 0.0 years.	

There were no stock options granted during the three months ended December 31, 2017 and December 31, 2016. The following is a summary of stock option activity during the three months ended December 31, 2017:

3 Months Ended

	Number of	Weighted average
	options	exercise price
Outstanding as of September 30, 2017	38,950	\$ 2.79
Granted	-	-
Exercised	(3,500)	2.58
Cancelled or Forfeited	-	-
Outstanding as of December 31, 2017	35,450	\$ 2.81

The intrinsic value of an option is the amount by which the fair value of the underlying stock exceeds its exercise price. As of December 31, 2017, the weighted average remaining contractual term for all outstanding and exercisable stock options was 2.5 years and their aggregate intrinsic value was \$334,810. During the three months ended December 31, 2017, the Company received proceeds of \$3,249 from the exercise of stock options. During the three months ended December 31, 2016, exercised stock options totaled 10,000 shares, resulting in \$17 of proceeds to the Company.

Restricted Stock

Note 4 - Stock Based Compensation

The Company's 2007 Stock Compensation Plan permits its Compensation Committee to grant stock-based awards, including stock options and restricted stock, to key employees and non-employee directors. The Company has made restricted stock grants that vest over one to ten years.

There were no restricted stock awards granted during the three months ended December 31, 2017 and December 31, 2016. Restricted stock transactions during the three months ended December 31, 2017 are summarized as follows:

		Weighted
	Number of	average grant
	shares	date fair value
Unvested shares as of September 30, 2017	370,530	\$ 15,24
Granted	-	-
Vested	(2,000)	13.59
Forfeited	(4,376)	15.46
Unvested as of December 31, 2017	364,154	\$ 15.25

Employee Stock Purchase Plan

Clearfield, Inc.'s ESPP allows participating employees to purchase shares of the Company's common stock at a discount through payroll deductions. The ESPP is available to all employees subject to certain eligibility requirements. Terms of the ESPP provide that participating employees may purchase the Company's common stock on a voluntary after-tax basis. Employees may purchase the Company's common stock at a price that is no less than the lower of 85% of the fair market value of one share of common stock at the beginning or end of each stock purchase period or phase. The ESPP is carried out in six month phases, with phases beginning on January 1 and July 1 of each calendar year. For the phases that ended on December 31, 2017 and December 31, 2016, employees purchased 14,242 and 11,144 shares at a price of \$10.41 and \$15.21 per share, respectively. After the employee purchase on December 31, 2017, 103,013 shares of common stock were available for future purchase under the ESPP.

Note 5 - Accounts Receivable	3 Months Ended
Note 5 - Accounts Receivable	Dec. 31, 2017
Notes to Financial Statements	
Financing Receivables [Text Block]	Note 5. Accounts Receivable
	Credit is extended based on the evaluation of a customer's financial condition and collateral is generally not required. Accounts that are outstanding longer than the contractual payment terms are considered past due. The Company writes off accounts receivable when they become uncollectible; payments subsequently received on such receivables are credited to the allowance for doubtful accounts. As of both December 31, 2017 and September 30, 2017, the balance in the allowance for doubtful accounts was \$79,085.
	See Note 7, "Major Customer Concentration" for further information regarding accounts receivable and net sales.

Note 6 - Inventories	3 Months Ended						
Note 6 - inventories	Dec. 31, 2017						
Notes to Financial Statements							
Inventory Disclosure [Text Block]	Note 6. Inventories						
	Inventories consist of the following as of:						
			December 31,		September 30,		
			2017				
	Raw materials	\$	6,012,095	\$	5,991,863		
	Work-in-progress		431,495		724,248		
	Finished goods		1,696,794		1,737,456		
	Inventories	\$	8,140,384	\$	8,453,567		
	During the quarter ended December 31, 2017, the Company adopted A 11, Inventory (Topic 330) Related to Simplifying the Measurement of Inventory which is measured using last-in, first-out or the retail inventory method. This adoption has applied prospectively. Therefore, prior periods were not retrospectively adjusted.	ch ap	plies to all invento	ry e	xcept inventory that		

Notes to Financial Statements						
Concentration Risk Disclosure [Text Block]	Note 7. Major Customer Concentration					
	The following table summarizes customers comprising 10% or more of net sales for the three months ended December 2017 and December 31, 2016:					
		Three Months Ended December 31,				
		2017	2016			
	Customer A	22%	28%			
	Customer B	12% 14%				
	As of December 31, 2017, Customers A and B accounted for 15% and 14% September 30, 2017, Customer B accounted for 19% of accounts receivable. Customers		, 1			

Note 7 - Major Customer Concentration 3 Months Ended

Dec. 31, 2017

Note 8 - Goodwill and Patents	3 Months Ended
Note 6 - Goodwill and Paterits	Dec. 31, 2017
Notes to Financial Statements	
Goodwill and Intangible Assets Disclosure [Text Block]	Note 8. Goodwill and Patents
	The Company analyzes its goodwill for impairment annually or at an interim period when events occur or changes in circumstances indicate potential impairment. The result of the analysis performed in the fourth quarter ended September 30, 2017 did not indicate an impairment of goodwill. During the quarter ended December 31, 2017, there were no triggering events that indicate potential impairment exists.
	The Company capitalizes legal costs incurred to obtain patents. Once accepted by either the U.S. Patent Office or the equivalent office of a foreign country, these legal costs are amortized using the straight-line method over the remaining estimated lives, not exceeding 20 years. As of December 31, 2017, the Company has 12 patents granted and multiple pending applications both inside and outside the United States.

Note 9 - Income Taxes	3 Months Ended
Note 9 - Ilicollie Taxes	Dec. 31, 2017
Notes to Financial Statements	
Income Tax Disclosure [Text Block]	Note 9. Income Taxes
	For the three months ended December 31, 2017, the Company recorded a benefit for income taxes of \$203,000, reflecting an effective tax rate of negative 27.4% The Tax Cut and Jobs Act of 2017 (the "Tax Reform Act") was enacted on December 22, 2017

For the three months ended December 31, 2017, the Company recorded a benefit for income taxes of \$203,000, reflecting an effective tax rate of negative 27.4%. The Tax Cut and Jobs Act of 2017 (the "Tax Reform Act") was enacted on December 22, 2017. The Tax Reform Act reduced certain federal corporate income tax rates effective January 1, 2018 and changed certain other provisions. The effective tax rate for the quarter ended December 31, 2017 is a blended rate reflecting the anticipated benefit of three quarters of federal tax rate reductions for fiscal 2018. Our first quarter tax benefit reflects a lower tax rate and a one-time benefit of \$384,000 related to the favorable impact of a revaluation of our net deferred tax liability that decreased the income tax provision for the quarter ended December 31, 2017 and reduced long-term deferred tax liabilities as of December 31, 2017. The final impact of the Tax Reform Act may differ due to and among other things, changes in interpretations, assumptions made by the Company, the issuance of additional guidance, and actions the Company may take as a result of the Tax Reform Act. Additionally, differences between the effective tax rate and the statutory tax rate are related to nondeductible meals and entertainment, favorable domestic manufacturing deduction and research and development credits.

As of December 31, 2017 and September 30, 2017, the Company had a remaining valuation allowance of approximately \$191,000 and \$159,000, respectively, related to state net operating loss carry forwards the Company does not expect to utilize. As a result of recording the impact of the Tax Reform Act on its deferred assets and liabilities, the Company recorded an increase in its valuation allowance against state net operating losses carried forward of approximately \$32,000 in the quarter ended December 31, 2017. Based on the Company's analysis and review of long-term forecasts and all available evidence, the Company has determined that there should be no further change in this existing valuation allowance in the quarter ended December 31, 2017.

For the three months ended December 31, 2016, the Company recorded a provision for income taxes of \$367,000, reflecting an effective tax rate of 29.5%. The primary difference between the effective tax rate and the statutory tax rate was related to nondeductible meals and entertainment, favorable domestic manufacturing deduction and research and development credits, expenses related to equity award compensation and favorable discrete items for the quarter from tax benefits related to stock-based compensation awards.

Deferred taxes recognize the impact of temporary differences between the amounts of the assets and liabilities recorded for financial statement purposes and these amounts measured in accordance with tax laws. The Company's realization of deferred tax temporary differences is contingent upon future taxable earnings. The Company reviewed its deferred tax asset for expected utilization using a "more likely than not" criteria by assessing the available positive and negative factors surrounding its recoverability.

As of December 31, 2017, we do not have any unrecognized tax benefits. It is the Company's practice to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. The Company does not expect any material changes in its unrecognized tax positions over the next 12 months.

Note 10 - Accounting	3 Months Ended
Pronouncements	Dec. 31, 2017
Notes to Financial Statements	
New Accounting Pronouncements and Changes in Accounting Principles [Text	Note 10. Accounting Pronouncements
Block]	Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (the "FASB") issued guidance creating Accounting Standards Codification ("ASC") Section 606, Revenue from Contracts with Customers. The new section will replace Section 605, "Revenue Recognition" and creates modifications to various other revenue accounting standards for specialized transactions and industries. The section is intended to conform revenue accounting principles with a concurrently issued International Financial Reporting Standards with previously differing treatment between United States practice and those of much of the rest of the world, as well as to enhance disclosures related to disaggregated revenue information. The updated guidance is effective for annual reporting periods beginning after December 15, 2017, and interim periods within that reporting period. Early application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is planning to complete an assessment of its revenue streams during the second and third quarters of fiscal 2018 to determine the impact that this standard will have on its business practices, financial condition, results of operations and disclosures. The updated guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The updated guidance requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required for customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The Company anticipates there will be expanded financial statement disclosures in order to comply with the updated guidance. The Company has not yet decided on the transition method upon adoption, but plans to select a transition method during the middle of fiscal 2018.

In February 2016, the FASB issued ASU 2016-02, *Leases*, which requires lessees to present right-of-use assets and lease liabilities on the balance sheet for all leases with terms longer than 12 months. The guidance is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements and is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is evaluating the impact the adoption of this ASU will have on our financial statements.

In January 2017, the FASB issued ASU 2017-04 which offers amended guidance to simplify the accounting for goodwill impairment by removing Step 2 of the goodwill impairment test. A goodwill impairment will now be measured as the amount by which a reporting unit's carrying value exceeds its fair value, limited to the amount of goodwill allocated to that reporting unit. This guidance is to be applied on a prospective basis effective for the Company's interim and annual periods beginning after January 1, 2020, with early adoption permitted for any impairment tests performed after January 1, 2017. The Company does not believe the adoption of this ASU will have a material impact on our financial statements.

Note 2 - Net Income Per Share	3 Months Ended				
(Tables)	Dec. 31, 2017				
Notes Tables					
Schedule of Earnings Per Share, Basic		Th	ree Months En	ded I	December 31,
and Diluted [Table Text Block]			2017		2016
	Net income	\$	943,158	\$	876,930
	Weighted average common shares		13,443,945		13,567,484
	Dilutive potential common shares		32,472		223,309
	Weighted average dilutive common shares outstanding		13,476,417		13,790,793
	Net income per common share:				
	Basic	\$	0.07	\$	0.06
	Diluted	\$	0.07	\$	0.06

Note 3 - Cash, Cash Equivalents and		3 Months Ended				
Investments (Tables)	Dec. 31, 2017					
Notes Tables						
Investments Classified by Contractual Maturity Date [Table Text Block]			December 31, 2017		September 30, 2017	
	Less than one year		\$	5,385,150	\$	5,937,150
	1-5 years			20,357,000		19,816,000
	Total		\$	25,742,150	\$	25,753,150

Note 4 - Stock Based Compensation		3 Months Ended			
(Tables)		Dec. 31, 2017			
Notes Tables					
Share-based Compensation, Stock Options, Activity [Table Text Block]			Number of options	V	Veighted average exercise price
	Outstanding as of September 30, 2017		38,950	\$	2.79
	Granted		-		-
	Exercised		(3,500)		2.58
	Cancelled or Forfeited		-		-
	Outstanding as of December 31, 2017		35,450	\$	2.81
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]			Number of shares		Weighted average grant date fair value
	Unvested shares as of September 30, 2017		370,530	\$	15,24
	Granted		-		-
	Vested		(2,000)		13.59
	Forfeited		(4,376)		15.46
	Unvested as of December 31, 2017		364 154	2	15.25

Note 6 - Inventories (Tables)	3 Months Ended						
Note 6 - inventories (Tables)	Dec.	31, 2017					
Notes Tables							
Schedule of Inventory, Current [Table Text			December 31,	S	September 30,		
Block]			2017		2017		
	Raw materials	\$	6,012,095	\$	5,991,863		
	Work-in-progress		431,495		724,248		
	Finished goods		1,696,794		1,737,456		
	Inventories	\$	8,140,384	\$	8,453,567		

Note 7 - Major Customer Concentration (Tables)		3 Months Ended Dec. 31, 2017		
Notes Tables				
Schedules of Concentration of Risk, by			Three Months Ended December 31,	
Risk Factor [Table Text Block]		_	2017	2016
	Customer A	_	22%	28%
	Customer B		12%	14%

Note 2 - Net Income Per Share - Net Income Per Common Share (Details) (USD \$)	3 Months Ended	
	Dec. 31, 2017	Dec. 31, 2016
Net income	\$ 943,158	\$ 876,930
Weighted average common shares (in shares)	13,443,945	13,567,484
Dilutive potential common shares (in shares)	32,472	223,309
Weighted average dilutive common shares outstanding (in shares)	13,476,417	13,790,793
Net income per common share:		
Basic (in dollars per share)	\$ 0.07	\$ 0.06
Diluted (in dollars per share)	\$ 0.07	\$ 0.06

Note 3 - Cash, Cash Equivalents and	3 Months Ended
Investments (Details Textual) (Maximum [Member])	Dec. 31, 2017
Maximum [Member]	
Held-to-maturity Securities, Investment Term	5 years

Note 3 - Cash, Cash Equivalents and Investments - CD Maturity Dates (Details) (USD \$)	Dec. 31, 2017	Sep. 30, 2017
Less than one year	\$ 5,385,150	\$ 5,937,150
1-5 years	20,357,000	19,816,000
Total	\$ 25,742,150	\$ 25,753,150

Note 4 - Stock Based Compensation	3 Months Ended		
(Details Textual) (USD \$)	Dec. 31, 2017	Dec. 31, 2016	
Allocated Share-based Compensation Expense	\$ 483,287	\$ 593,746	
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	4,431,952		
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	6 years 292 days		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	0	
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	2 years 182 days		
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	334,810		
Proceeds from Stock Options Exercised	3,249	17	
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	3,500	10,000	
Employee Stock Purchase Plan [Member]			
Share-based Compensation Arrangement by Share-based Payment Award, Market Price Percentage, Offering Date	85.00%		
Stock Issued During Period, Shares, Employee Stock Purchase Plans	14,242	11,144	
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price	\$ 10.41	\$ 15.21	
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	103,013		
Restricted Stock [Member]			
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			
Restricted Stock [Member] Employees [Member] Stock Compensation Plan 2007 [Member]			

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	0	0
Restricted Stock [Member] Employee and Non-Employee Directors [Member] Stock Compensation Plan 2007 [Member] Minimum [Member]		
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year	
Restricted Stock [Member] Employee and Non-Employee Directors [Member] Stock Compensation Plan 2007 [Member] Maximum [Member]		
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years	
Selling, General and Administrative Expenses [Member]		
Allocated Share-based Compensation Expense	441,257	539,046
Cost of Sales [Member]		
Allocated Share-based Compensation Expense	\$ 42,030	\$ 54,700

Note 4 - Stock-based Compensation - Stock Option Activity (Details) (USD \$)	3 Months Ended		
	Dec. 31, 2017	Dec. 31, 2016	
Options, outstanding (in shares)	38,950		
Weighted-average exercise price, outstanding (in dollars per share)	\$ 2.79		
Exercised (in shares)	(3,500)	(10,000)	
Exercised (in dollars per share)	\$ 2.58		
Options, outstanding (in shares)	35,450		
Weighted-average exercise price, outstanding (in dollars per share)	\$ 2.81		

Note 4 - Stock-based Compensation	3 Months Ended	
 Restricted Stock Transactions (Details) (Restricted Stock [Member], USD \$) 	Dec. 31, 2017	
Restricted Stock [Member]		
Balance, unvested shares (in shares)	370,530	
Balance, weighted-average grant date fair value (in dollars per share)	\$ 1,524	
Granted (in shares)		
Granted (in dollars per share)		
Vested (in shares)	(2,000)	
Vested (in dollars per share)	\$ 13.59	
Forfeited (in shares)	(4,376)	
Forfeited (in dollars per share)	\$ 15.46	
Balance, unvested shares (in shares)	364,154	
Balance, weighted-average grant date fair value (in dollars per share)	\$ 15.25	

Note 5 - Accounts (Details Textual)		Dec. 31, 2017	Sep. 30, 2017
Allowance for Doubtful A Receivable, Current	ccounts	\$ 79,085	\$ 79,085

Note 6 - Inventories - Components of Inventory (Details) (USD \$)	Dec. 31, 2017	Sep. 30, 2017
Raw materials	\$ 6,012,095	\$ 5,991,863
Work-in-progress	431,495	724,248
Finished goods	1,696,794	1,737,456
Inventories	\$ 8,140,384	\$ 8,453,567

Note 7 - Major Customer	3 Months Ended	12 Months Ended
Concentration (Details Textual) (Accounts Receivable [Member], Customer Concentration Risk [Member])	Dec. 31, 2017	Sep. 30, 2017
Customer A [Member]		
Concentration Risk, Percentage	15.00%	
Customer B [Member]		
Concentration Risk, Percentage	14.00%	19.00%

Note 7 - Major Customer	3 Months Ended		
Concentrations - Customers Comprising 10% or More of Net Sales (Details) (Customer Concentration Risk [Member], Sales Revenue, Net [Member])	Dec. 31, 2017	Dec. 31, 2016	i
Customer A [Member]			
Concentration Risk, Percentage	22.00%	28.00%	
Customer B [Member]			
Concentration Risk, Percentage	12.00%	14.00% [1	1]
[1] Less than 10%			

Ī	Note 8 - Goodwill and Patents (Details Textual) (USD \$) In Thousands, unless otherwise specified	3 Months Ended	
		Dec. 31, 2017	Sep. 30, 2017
	Goodwill, Impairment Loss	\$0	\$ 0
	Number of Patents Granted	12	
	Patents [Member]		
	Finite-Lived Intangible Asset, Useful Life	20 years	

Note 9 - Income Taxes (Details	3 Months Ended		
Textual) (USD \$)	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2017
Income Tax Expense (Benefit)	\$ (203,000)	\$ 367,000	
Effective Income Tax Rate Reconciliation, Percent	27.40%	29.50%	
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability	(384,000)		
Unrecognized Tax Benefits	0		
State and Local Jurisdiction [Member]			
Operating Loss Carryforwards, Valuation Allowance	191,000		159,000
State and Local Jurisdiction [Member] Deferred Tax Assets Related to Operating Loss Carryforwards [Member]			
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			